Paysign sees Q3 revenue $19.5M-$20.5M, consensus $18.93M

“For the third quarter of 2025, we expect total revenue to be in the range of $19.5 million to $20.5 million, reflecting continued strength for our pharma patient affordability business and the contribution of the new plasma centers to our plasma business. We expect plasma revenues to be approximately 60% of revenue and pharma patient affordability to be approximately 37% of revenue. Gross profit margins are expected to be approximately 59% due to the higher mix of plasma revenue and impact from startup costs related to the new patient services contact center. Operating expenses are expected to be between $10.5 million and $11.5 million, of which depreciation and amortization will be approximately $2.2 million and stock-based compensation will be approximately $1.4 million. Adjusted EBITDA is expected to be in the range of $4.5 million to $5.0 million, or approximately 23.1% to 24.4% of revenue,” Baker concluded.